About bivalirudin
Direct thrombin inhibitor anticoagulant
Used for
- Anticoagulation during percutaneous coronary intervention (PCI), including in acute coronary syndromes.
- Anticoagulation during PCI in patients with heparin-induced thrombocytopenia.
Usual adult dose
PCI: 0.75 mg/kg IV bolus, then 1.75 mg/kg/hour during the procedure; dosing may vary by indication and kidney function.
Common side effects
- Bleeding
- Nausea
- Back pain
- Low blood pressure
Important warnings
- Serious bleeding can occur; monitor for bleeding and blood-count changes.
- Dose adjustment may be needed in severe kidney impairment.
- Use caution with other medicines that increase bleeding.
- Only for intravenous administration by trained healthcare professionals.
Pregnancy
Human pregnancy data are limited. Use only when clearly needed; weigh potential benefits against risks.
Breastfeeding
It is unknown whether bivalirudin passes into breast milk. Consider the medicine’s importance when deciding about breastfeeding.
Interactions
- Anticoagulants and antiplatelet medicines can increase bleeding risk.
- Thrombolytic medicines can increase bleeding risk.
- Nonsteroidal anti-inflammatory drugs may increase bleeding risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.